N

NewLimit

Develops epigenetic medicines to extend healthspan

Group Lead - Immunology

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeSouth San Francisco, CA, USA$180k - $240kIn-person

About the Job

Requirements

  • A Ph.D. in cell biology, immunology, or a related field, or comparable industry experience.
  • Experience leading a team and managing direct reports.
  • Experience with therapeutics development, ideally leading part of a discovery or development process in an immunology, infectious disease, or inflammatory disease setting.
  • Deep knowledge of immunology and lymphocyte biology.

Responsibilities

  • Lead a team of scientists and research associates to develop reprogramming therapies.
  • Develop functional assays and pre-clinical models for inflammatory and infectious disease indications.
  • Evaluate reprogramming payloads using functional assays and pre-clinical models to validate payloads, select leads, and progress pre-clinical candidates.
  • Collaborate with the Single Cell Technology, Epigenetic Editing, and Predictive Modeling teams to design, build, and test reprogramming interventions.
  • Contribute to product development decisions, company-wide goals, and the technology platform, and help build the company alongside the team.
  • Contribute to day-to-day execution alongside the team.

Desired Qualifications

  • Direct experience with T cell biology, including relevant functional assays, pre-clinical models, and experimental methods.
  • Experience with in vivo nucleic acid delivery technologies.
  • Experience with pooled screening and related functional genomics methods.
  • Strong molecular biology foundations and experience designing transgenic constructs.
  • Experience with iterative product development cycles, such as design-build-test-learn.
  • Knowledge of aging biology, computational biology, and machine learning.

About the Company

NewLimit

Develops epigenetic medicines to extend healthspan

NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.

Company size
51-200
Company stage
Series C
Total funding
$650M
Headquarters
South San Francisco, CA
Founded
2022

Recently Posted Jobs

Explore more opportunities at NewLimit

See more jobs